This compound is primarily utilized in the development of targeted cancer therapies, particularly in the field of proteolysis-targeting chimeras (PROTACs). It functions as a key linker molecule, connecting a target protein-binding moiety to an E3 ubiquitin ligase-recruiting moiety. This enables the selective degradation of disease-causing proteins, such as those involved in cancer progression. Its application is significant in preclinical research for designing novel drugs that can degrade specific oncogenic proteins, offering a promising approach for treating cancers resistant to traditional therapies. Additionally, it is explored in studies focused on understanding protein degradation pathways and their role in cellular processes.